Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 61, Issue 4, Pages 523-533Publisher
SPRINGER
DOI: 10.1007/s00262-011-1109-0
Keywords
Farnesyltransferase inhibitors; Immunomodulatory; T-bet; Large granular lymphocyte leukemia; Interferon; Histone acetylation
Categories
Funding
- H. Lee Moffitt Cancer Center Flow Cytometry Core Facility
- [NCI R01CA11211201]
- [NIH AI056213]
- [U54RR019397-05]
Ask authors/readers for more resources
Large granular lymphocyte (LGL) leukemia is a chronic lymphoproliferative disease in which T-bet [T-box transcription factor 21 gene (tbx21)] overexpression may play a pathogenic role. T-bet orchestrates the differentiation of mature peripheral T-cells into interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha producing CD4+ T-helper type I (Th1) and CD8+ T cytotoxic cells that are necessary for antiviral responses. When IL-12 is produced by antigen-presenting cells, T-bet expression is induced, causing direct stimulation of ifng gene transcription while simultaneously acting as a transcriptional repressor of the IL4 gene, which then leads to Th1 dominance and T-helper type 2 differentiation blockade. Additionally, T-bet has been shown to regulate histone acetylation of the ifng promoter and enhancer to loosen condensed DNA, creating greater accessibility for other transcription factor binding, which further amplifies IFN gamma production. We found that treatment with a farnesyltransferase inhibitor tipifarnib reduced Th1 cytokines in LGL leukemia patient T-cells and blocked T-bet protein expression and IL-12 responsiveness in T-cells from healthy donors. The mechanism of suppression was based on modulation of histone acetylation of the ifng gene, which culminated in Th1 blockade.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available